Group 1 - US stock indices showed mixed performance, with the Chinese concept index down by 1.54%. Hong Kong's three major indices opened lower, with the Hang Seng Index down 0.53% and the Hang Seng Tech Index down 0.51% [1] - CXO concept stocks in Hong Kong saw initial gains, with Kanglong Chemical rising over 10%, and other companies like WuXi Biologics and Tigermed also experiencing significant increases [1] - The Hang Seng Medical ETF (513060) opened high and saw a nearly 2% increase, with active trading and a turnover of nearly 800 million yuan, indicating strong investor interest [1] Group 2 - CXO industry leaders are showing signs of stabilization, with expectations for marginal improvements in the second half of the year due to steady growth in R&D investments from the top 30 global pharmaceutical companies [2] - The GLP-1 peptide and small molecule weight loss drug sectors are experiencing high demand, with ample customer orders, while the international situation is expected to stabilize following recent trade negotiations [2] - The anticipated interest rate cuts by the Federal Reserve by 2025 are expected to improve liquidity and revive the global innovative drug industry [2] Group 3 - Focus on the equipment sector's resilience and new technology directions such as AI in healthcare and brain-computer interfaces, as the medical industry faces fewer compliance impacts [3] - The Hang Seng Medical ETF (513060) is highlighted for its efficient layout and strong representation of the medical device, pharmaceutical, and biotechnology sectors, with a low tracking error and high liquidity [3]

Group 1 - The A500 Index has shown a slight increase of 0.03% as of July 25, 2025, with notable stock performances including Kanglong Chemical rising by 10.05% and Yunda Holdings by 6.93% [1] - The A500 ETF managed by Harvest has a trading turnover of 6.13% and a transaction volume of 8.09 billion yuan, with an average daily transaction of 31.59 billion yuan over the past month [3] - The A500 ETF's latest scale reached 132.12 billion yuan, and it has seen a net value increase of 10.10% over the past six months [3] Group 2 - The top ten weighted stocks in the CSI A500 Index as of June 30, 2025, include Kweichow Moutai, CATL, and Ping An Insurance, collectively accounting for 20.67% of the index [3] - The Shanghai Composite Index closed at 3605.73 points, marking a 0.65% increase and reaching a new high for the year, surpassing the 3600-point mark for the first time in three and a half years [3] - According to Everbright Securities, domestic policies have shifted towards a focus on fundamental and liquidity-driven strategies since September of last year, maintaining a proactive stance while allowing flexibility to address potential external risks [4]

Group 1 - The CXO concept stocks in the Hong Kong market experienced an initial rise, with Kanglong Chemical (300759) increasing by over 10% [1] - Zhaoyan New Drug (603127) saw a rise of over 6%, while WuXi Biologics increased by over 4% [1] - Other companies such as Tigermed (300347) and WuXi AppTec (603259) also followed the upward trend [1] Group 2 - Investors can buy Hong Kong stocks through A-share accounts without the need for the Hong Kong Stock Connect, allowing for T+0 trading [1]

Core Viewpoint - A recent incident of violence in a laboratory of Kanglong Chemical has raised concerns about the company's internal culture and management, coinciding with a disappointing earnings forecast that highlights declining profitability despite revenue growth [3][4][5]. Financial Performance - Kanglong Chemical's revenue forecast for the first half of 2025 is projected to be between 6.3 billion and 6.5 billion yuan, representing a year-on-year growth of 13% to 16%. However, net profit is expected to decline by 36% to 39%, amounting to 679 million to 713 million yuan [3][4]. - The company's revenue for 2023 was 11.538 billion yuan, a growth of 12.39%, marking the lowest growth rate since 2015 and the first time in nine years that growth fell below 20% [4]. - The forecast for 2024 indicates a further slowdown, with revenue growth expected to drop to single digits at 6.39%, and a significant decline in net profit by 26.8% [4]. Business Segments - Kanglong Chemical's CGT and large molecule business has been identified as a drag on overall performance, with revenue for this segment in 2024 expected to be 408 million yuan, a decline of 4%, while costs surged by 33% to 612 million yuan, resulting in a record loss of 204 million yuan [6]. - The company has been facing challenges in the CGT sector due to a slowdown in global drug development demand and increased competition, leading to downward pressure on service prices [6][7]. Market Dynamics - Domestic revenue from Chinese clients is projected to decline by 6.46% to 1.847 billion yuan, while revenue from North American clients is expected to grow by 6.11% to 7.853 billion yuan, indicating a disparity in performance across regions [8]. - The company is advised to enhance early-stage development collaborations and explore new service models to improve client retention and pricing power [8]. Shareholder Activity - Significant shareholder sell-offs have raised concerns, with major shareholders having reduced their holdings by 77.95 million shares since 2022, equivalent to 4.835 billion yuan, which is nearly three times the company's projected net profit for 2024 [9][10]. - The accelerated pace of share reduction and the loosening of concentrated shareholding structures may weaken governance and control within the company, potentially impacting strategic decision-making [10].

Core Viewpoint - The recent incident of two employees fighting in the office has raised concerns about the company culture at Kanglong Chemical (康龙化成) and its impact on the company's reputation and operations [1][3][4]. Company Overview - Kanglong Chemical, established in 2004, is a leading global integrated pharmaceutical research and development service platform, listed on A-share and H-share markets in 2019 [2][4]. - The company experienced a significant stock price increase, reaching a peak market value of nearly 200 billion yuan in 2021, but has since seen its market value shrink to approximately 46.8 billion yuan, a loss of over 140 billion yuan [2][7]. Financial Performance - The company's profit growth has slowed down, with a projected net profit of approximately 6.79 billion to 7.13 billion yuan for the first half of 2025, representing a year-on-year increase of 36% to 39%. However, the adjusted net profit under non-IFRS is expected to grow only by 6% to 11% [2][7]. - Kanglong Chemical's revenue growth has also decelerated, with expected revenues of 63.33 billion to 65.01 billion yuan for the first half of 2025, reflecting a year-on-year growth of 13% to 16% [7]. Shareholder Activity - There has been significant shareholder reduction in holdings, with total cashing out exceeding 20 billion yuan since 2022. The actual controller and related parties have cashed out around 3 billion yuan [2][8][9]. - Notably, major shareholders have reduced their stakes significantly, with one entity alone cashing out approximately 5.4 billion yuan [8]. Company Culture and Employee Relations - The company promotes a culture of "employees first, customers second," focusing on employee training and development [5]. - The recent incident of fighting among employees has sparked public criticism regarding the company's internal culture and management practices, with many questioning the adequacy of resources and support for employees [3][4][6].

Group 1 - HSK47388, a self-developed oral drug by the company, has received FDA approval to initiate clinical trials for the treatment of autoimmune diseases, showing significant dose-dependent anti-inflammatory effects and good safety profile in preclinical studies [1] - The drug's large safety window provides a favorable foundation for subsequent clinical research, potentially filling existing treatment gaps for autoimmune disease patients [1] Group 2 - Kanglong Chemical's net profit for the first half of 2025 is expected to decline by 36% to 39%, reflecting short-term pressures in the CRO industry due to global biopharmaceutical investment slowdown, order delays, and rising costs [2] - Dezheng Health anticipates a net loss of approximately 25 million to 50 million yuan for the first half of the year, a significant decline from a profit of 10.15 million yuan in the same period last year, attributed to the impact of centralized procurement and high sales expenses [3] - China National Pharmaceutical's acquisition of 95.09% of Lixin Pharmaceutical is expected to enhance its innovative drug revenue share, reflecting a trend of domestic pharmaceutical companies strengthening their competitive edge through mergers and acquisitions [4] - Baicheng Pharmaceutical forecasts a net profit decline of over 95% for the first half of 2025, with government subsidies contributing significantly to its profits, indicating challenges in its core business capabilities during its strategic transformation [5]

| 证券代码：300759 证券简称：康龙化成 | 公告编号：2025-038 | | --- | --- | | 康龙化成（北京）新药技术股份有限公司 | | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | | 记载、误导性陈述或重大遗漏。 | | | 以下为本公司的 2025 年半年度业绩预告。本业绩预告所载之财务数据未经 | | | 审计，除经调整的非《国际财务报告准则》下归属于上市公司股东的净利润或另 | | | 有注释外，本业绩预告所载之财务数据根据中国企业会计准则编制。 | | | 一、本期业绩预计情况 | | | 预计营业收入、归属于上市公司股东的扣除非经常性损益后的净利润以及经 | | | 调整的非《国际财务报告准则》下归属于上市公司股东的净利润同向上升，预计 | | | 归属于上市公司股东的净利润同向下降。 | | | 项 目 本报告期 上年同期 | | | 营收：633,304.36 万元–650,117.75 万元 | | | 营业收入 营收：560,446.34 万元 | | | 比上年同期增长：13%–16% | | | 归属于上市公司股东 盈利：67 ...

[WuXi AppTec 2025 Half-Year Performance Forecast](index=1&type=section&id=WuXi%20AppTec%20(Beijing)%20Co.%2C%20Ltd.%202025%20Half-Year%20Performance%20Forecast) WuXi AppTec provides its preliminary financial outlook for the first half of 2025, detailing expected changes in key performance indicators [Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company anticipates year-over-year growth in H1 2025 operating revenue, net profit excluding non-recurring gains/losses, and adjusted non-IFRS net profit, while net profit attributable to shareholders is expected to decline by 36%-39% due to significant non-recurring gains in the prior year Key Financial Indicators for H1 2025 Performance Forecast | Item | Current Period (2025H1) | Prior Period (2024H1) | Change | | :--- | :--- | :--- | :--- | | **Operating Revenue** | RMB 6,333.0436 million - RMB 6,501.1775 million | RMB 5,604.4634 million | Growth 13%–16% | | **Net Profit Attributable to Shareholders** | RMB 679.1758 million - RMB 712.5779 million | RMB 1,113.4030 million | Decline 36%–39% | | **Net Profit Excluding Non-Recurring Gains/Losses** | RMB 624.2831 million - RMB 647.5772 million | RMB 465.8829 million | Growth 34%–39% | | **Adjusted Non-IFRS Net Profit** | RMB 731.6822 million - RMB 766.1955 million | RMB 690.2662 million | Growth 6%–11% | | **Basic Earnings Per Share** | RMB 0.3858 - RMB 0.4048/share | RMB 0.6282/share | - | - The company estimates H1 2025 non-recurring gains/losses attributable to shareholders to be approximately **RMB 60 million to RMB 70 million**, primarily comprising government subsidies, fair value changes in financial assets, and wealth management product gains/losses[7](index=7&type=chunk) - The company uses **adjusted non-IFRS net profit** as a supplementary financial metric, excluding the impact of share-based payments, exchange gains/losses, equity investment gains/losses, convertible bond-related gains/losses, and other incidental or non-operating items, to better assess core business performance[8](index=8&type=chunk) [Communication with Accounting Firm](index=3&type=section&id=II.%20Communication%20with%20Accounting%20Firm) This performance forecast has not been audited or pre-audited by an accounting firm - This performance forecast has not been audited or pre-audited by an accounting firm[10](index=10&type=chunk) [Explanation of Performance Changes](index=3&type=section&id=III.%20Explanation%20of%20Performance%20Changes) Performance changes are primarily driven by robust core business growth and a significant year-over-year decrease in non-recurring gains/losses, impacting net profit attributable to shareholders - The company steadfastly implements its core strategy of **'full-process, integrated, internationalized, multi-therapy'**, driven by customer needs, deepening global presence, and strengthening technology platforms to achieve sustained core business growth[11](index=11&type=chunk) - Non-recurring gains/losses for the reporting period are estimated at **RMB 60 million to RMB 70 million**, a significant year-over-year decrease of approximately **RMB 580 million** compared to **RMB 647.5201 million** in the prior period (primarily from the disposal of PROTEOLOGIX, INC. equity), which is the main reason for the decline in net profit attributable to shareholders[11](index=11&type=chunk) - Despite the decline in net profit attributable to shareholders, core operating indicators show strong performance, with Q2 2025 operating revenue growing by **13.11%**, net profit excluding non-recurring gains/losses by **23.33%**, and adjusted non-IFRS net profit by **13.67%** based on the forecast median[11](index=11&type=chunk) [Other Relevant Information](index=3&type=section&id=IV.%20Other%20Relevant%20Information) The company advises investors that this performance forecast is a preliminary, unaudited estimate by the finance department, with detailed financial data to be disclosed in the 2025 half-year report on the Shenzhen and Hong Kong stock exchanges, urging caution regarding investment risks - This performance forecast data represents a preliminary, unaudited estimate by the company's finance department[13](index=13&type=chunk) - Detailed H1 2025 performance data will be disclosed in the official reports published by the company on the Shenzhen Stock Exchange and Hong Kong Stock Exchange[14](index=14&type=chunk) [Reference Documents](index=4&type=section&id=V.%20Reference%20Documents) Reference documents for this announcement include the Board of Directors' explanation regarding the performance forecast and other documents required by the Shenzhen Stock Exchange - Reference documents include: - Board of Directors' explanation regarding the current period's performance forecast - Other documents required by the Shenzhen Stock Exchange[15](index=15&type=chunk)

康龙化成（300759）公告，信息披露义务人信中康成及其一致行动人信中龙成合计减持公司股份5521.3 万股，占公司总股本的3.36%。此次减持包括集中竞价交易和大宗交易两种方式，减持期间为2023年1 月10日至2025年7月9日。此次减持是由于信息披露义务人自身资金需求以及公司历次激励计划归属的限 制性股票上市、回购注销股份、权益分派等原因导致股份比例被动变动。未来12个月内，信息披露义务 人将继续减持股份并计划在未来12个月内无增持计划。 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-037 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东权益变动 触及 1%和 5%整数倍的提示性公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）及其一致行 动人深圳市信中龙成投资合伙企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于近日收到 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）（以下简称"信 中康成"）及其一致行动人深圳市信中龙成投资合伙企业（有限合伙）（以下简称 "信中龙成"）出具的《股份减持进展告知函》，获悉信中康成和信中龙成因减持、 公司总股本变动等原因导致权益变动触及 1%和 5%的整数倍。现将有关情况公 告如下： 1.基本情况 信息披露义务人 （一） 深圳市信中康成投资合伙企业（有限合伙） 住所 深圳市前海深港合作区南山街道兴海大道 3046 号香江金 融大厦 1314-B8 信息披露义务人 （二） 深圳市信 ...